Pharmaceuticals
Soligenix's HyBryte Shows Promising Results in Rare Cancer Treatment
Soligenix reports significant progress in treating cutaneous T-cell lymphoma (CTCL) with its experimental therapy HyBryte, demonstrating 75% treatment success after 18 weeks of clinical trials. The breakthrough offers potential hope for patients with this challenging rare skin cancer.
NanoViricides Highlights Potential Antiviral Solution Amid Changing COVID Booster Recommendations
NanoViricides' President Dr. Anil Diwan comments on the FDA's updated COVID-19 booster policy, emphasizing the need for alternative antiviral treatments and positioning the company's NV-387 drug candidate as a potential solution for respiratory viral infections.
Tonix Pharmaceuticals CEO Highlights Strategic Developments at A.G.P. Healthcare Showcase
Tonix Pharmaceuticals CEO Seth Lederman shared key strategic insights during a fireside chat, emphasizing the company's integrated business model and advanced clinical pipeline, with particular focus on potential treatments for fibromyalgia and potential defense-related medical innovations.
Telomir Pharmaceuticals Secures $3M Investment to Advance Age-Reversal Research
Telomir Pharmaceuticals has received a strategic $3 million equity investment from The Bayshore Trust, bolstering its efforts to develop potential breakthrough therapies targeting age-related diseases and longevity.
Aditxt Terminates Acquisition Agreement with Appili Therapeutics
Aditxt Inc. has decided to end its planned acquisition of Appili Therapeutics, citing a lack of strategic alignment. The termination highlights potential challenges in healthcare innovation partnerships.
CNS Pharmaceuticals Advances Brain Cancer Treatment, Reports Q1 Financial Results
CNS Pharmaceuticals is progressing its brain cancer treatment TPI 287, with increased R&D spending and plans for a Phase 2 study in recurrent glioblastoma multiforme, while maintaining financial runway into 2026.
NanoViricides Advances Broad-Spectrum Antiviral Drug, Eyes Multiple Phase II Trials
NanoViricides is progressing its NV-387 drug candidate across multiple viral infections, with pending Phase II trials for MPox and emerging programs for measles and avian flu, highlighting significant potential in antiviral treatment development.
Nutriband Expands Pharma Footprint with Strategic Partnerships
Nutriband Inc. strengthens its market position through strategic alliances with Charlotte FC and Kindeva Drug Delivery, focusing on its innovative abuse-deterrent transdermal drug delivery technology.
Telomir Pharmaceuticals Reveals Innovative Silver(II) Antimicrobial Drug Candidate
Telomir Pharmaceuticals has developed Telomir-Ag2, a novel Silver(II) complex with broad-spectrum antimicrobial properties targeting significant medical markets including wound care and infection treatment.
NanoViricides Advances Promising Antiviral Drug Against Measles and MPox
NanoViricides is developing NV-387, a potential breakthrough treatment for Measles and MPox amid rising global case counts and limited medical interventions. The drug represents a critical advancement in addressing urgent infectious disease challenges.
Silo Pharma Advances PTSD Treatment with FDA-Requested Safety Study
Silo Pharma is conducting a critical safety study on its intranasal PTSD treatment SPC-15, which could potentially provide a new therapeutic option for patients struggling with stress-related disorders by meeting FDA requirements for clinical advancement.
Tonix Pharmaceuticals Bolsters Leadership with Experienced Executive Joseph Hand
Tonix Pharmaceuticals strengthens its executive team by appointing Joseph Hand as General Counsel and EVP of Operations, bringing extensive corporate experience ahead of a potential FDA approval for its fibromyalgia treatment.
CNS Pharmaceuticals Raises $5 Million in Public Offering to Advance Brain Cancer Research
CNS Pharmaceuticals secures $5 million in funding through a public offering, aimed at supporting the development of innovative brain cancer treatments, with a focus on its lead drug candidate Berubicin.
Researchers Highlight Promising Anticancer Natural Product Synthesis Challenges
A systematic review of heterocyclic natural products reveals significant potential for anticancer drug development while identifying key challenges in synthesizing these compounds efficiently and sustainably.
Nutriband Develops Innovative Abuse-Deterrent Fentanyl Patch to Address Opioid Crisis
Nutriband Inc. has developed AVERSA™ Fentanyl, a technologically advanced transdermal patch designed to provide effective pain management while mitigating potential opioid abuse risks. The innovation represents a strategic approach to addressing the ongoing public health challenge of the opioid epidemic.
CNS Pharmaceuticals Secures Orphan Drug Designation for Brain Cancer Treatment
CNS Pharmaceuticals has transferred Orphan Drug Designation for TPI 287, a promising microtubule-stabilizing drug targeting brain cancer and neurological conditions. The designation could provide significant market advantages and potential treatment options for patients with challenging neurological disorders.
Tonix Pharmaceuticals Advances Fibromyalgia Drug, Reports Q1 Financial Results
Tonix Pharmaceuticals is poised for potential FDA approval of TNX-102 SL, a novel non-opioid fibromyalgia treatment, while maintaining a robust research pipeline and strong cash position. The drug could represent a significant breakthrough in fibromyalgia treatment after more than 15 years without a new drug class.
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate Through Critical Toxicity Studies
Quantum BioPharma has completed key 90-day toxicity studies for its multiple sclerosis drug candidate Lucid-21-302, positioning the company to file an Investigational New Drug application with the FDA and potentially develop a first-in-class MS therapy.
NRx Pharmaceuticals Set to Release Q1 2025 Financial Results and Provide Corporate Update
NRx Pharmaceuticals will disclose its first quarter 2025 financial performance and host a conference call, offering insights into its ongoing clinical-stage therapeutics development for central nervous system disorders.
Diplomatic Trade Acquires Major Stake in Turkish Pharmaceutical Company, Targets $300M IPO
Diplomatic Trade Ltd and its investment arm have secured a 49% equity position in a Turkish pharmaceutical company, with plans to launch a bio-manufacturing facility in the UAE and pursue a potential $300 million IPO in late 2025.
Nutriband Advances Abuse-Deterrent Fentanyl Patch in Response to Opioid Crisis
Nutriband is developing an innovative abuse-deterrent transdermal fentanyl patch amid shifting FDA regulations and ongoing efforts to combat opioid misuse. The technology represents a potential breakthrough in safer pain management strategies.
ABVC BioPharma Secures Japanese Patent for Innovative Depression Treatment
ABVC BioPharma has obtained a Japanese patent for its botanical-based Major Depressive Disorder treatment ABV-1504, expanding its global intellectual property portfolio and positioning the company for potential market entry in Japan's robust pharmaceutical landscape.
Scinai Immunotherapeutics Turns Financial Corner with $4.8 Million Net Gain
Biotechnology company Scinai Immunotherapeutics reports a significant financial turnaround in 2024, transforming a previous year's loss into a net gain through strategic financial management and early revenue generation.
Telomir Pharmaceuticals Advances Neurological Research with Novel Cellular Restoration Candidate
Telomir Pharmaceuticals reveals promising preclinical data for Telomir-1, a small molecule targeting cellular decline, with potential applications in autism spectrum disorder and rare neurological conditions. The research demonstrates potential breakthrough in understanding age-related cellular deterioration.
Dynamic Global Events to Host Life Science Meeting Planners Summit in Philadelphia
Dynamic Global Events will convene top life science industry professionals for a networking and information-sharing summit in Philadelphia, addressing critical collaboration needs in the sector.
Pacylex Pharmaceutical Explores N-myristoyltransferase Inhibitors as Potential ADC Cancer Therapies
Pacylex Pharmaceuticals is presenting innovative research on N-myristoyltransferase (NMT) inhibitors as potential payloads for antibody drug conjugates (ADCs), highlighting promising early clinical results in cancer treatment across multiple tumor types.
NanoViricides to Present at D. Boral Capital Inaugural Global Conference, Highlighting Antiviral Drug Development
NanoViricides, a clinical-stage biotech company specializing in nanomedicine-based antiviral treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its advanced drug candidates targeting respiratory viral infections and other diseases.
Soligenix's HyBryte Shows Promising Results in CTCL Treatment, Offering New Hope for Rare Skin Cancer Patients
Biotechnology company Soligenix has reported impressive interim results for HyBryte, a novel topical treatment for cutaneous T-cell lymphoma (CTCL), demonstrating a 75% response rate and potential to address a significant unmet medical need.
Soligenix Advances Treatment for Rare Skin Cancer with HyBryte™ Therapy
Soligenix's HyBryte™ therapy shows promise in treating early-stage cutaneous T-cell lymphoma, potentially addressing a significant gap in rare disease treatments within a rapidly growing global market.
Nutriband Advances Abuse-Deterrent Transdermal Drug Technology, Eyes 2025 Commercialization
Nutriband is positioning itself for potential market expansion by developing innovative abuse-deterrent transdermal pharmaceutical products with projected peak annual sales exceeding $330 million for its Fentanyl and Buprenorphine patches.